Company Profile

Intersect ENT, Inc. is a global ear, nose, and throat (ENT) medical technology company. The Company's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, such as VenSure and CUBE.

Employees

433

Sector

Medical Equipment, Supplies & Distribution

More about the company

17/05/22	Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Healthcare Equipment Select Industry Index	CI
17/05/22	Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P TMI Index	CI
17/05/22	Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Global BMI Index	CI
13/05/22	Medtronic Completes Purchase Of US Medical Device Group Intersect ENT	MT
13/05/22	Medtronic Completes Purchase of Intersect ENT	MT
13/05/22	Intersect ENT, Inc.(NasdaqGM:XENT) dropped from NASDAQ Composite Index	CI
13/05/22	Hemostasis, LLC acquired Fiagon AG Medical Technologies from Intersect ENT, Inc.	CI
13/05/22	Medtronic plc completed the acquisition of Intersect ENT, Inc..	CI
05/05/22	Intersect ENT, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
19/04/22	Intersect ENT, Inc. Enters into Amendment No.1 to Facility Agreement	CI
09/03/22	Intersect ENT, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
25/01/22	Intersect ENT Reports Positive Data From Real-World Evidence Study of Propel Sinus Implants	MT
25/01/22	Intersect ENT®, Inc. Announces Positive Results of Observational	CI

13/12/21	Berenberg Bank Terminates Coverage on a Number of Companies Due to Analysts' Departures From the Firm	MT
12/08/21	INTERSECT ENT : SVB Leerink Downgrades Intersect ENT to Market Perform From Outperform; Price Target is $28.25	MT
10/08/21	INTERSECT ENT : BTIG Downgrades Intersect ENT to Neutral From Buy	MT
09/08/21	INTERSECT ENT : Canaccord Genuity Downgrades Intersect ENT to Hold from Buy, Adjusts Price Target to $28.25 from $29	MT
09/08/21	INTERSECT ENT : Berenberg Bank Adjusts Intersect ENT Price Target to $28.25 From $18, Maintains Hold Rating	MT

13/05/22	INTERSECT ENT, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/05/22	INTERSECT ENT, INC. : Other Events (form 8-K)	AQ
05/05/22	INTERSECT ENT, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
19/04/22	INTERSECT ENT, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
24/03/22	INTERSECT ENT, INC. : Other Events (form 8-K)	AQ

16/09/20	Intersect ENT : kündigt Vereinbarung zur Übernahme der Fiagon AG Medical Technologies für 60 Millionen Euro über einen Zahlungszeitraum von drei Jahren an
09/07/20	Wall Street, portée par les géants de la tech, repart de l'avant
08/07/20	Wall Street monte à l'ouverture au lendemain d'un repli

Date	Insider	Type	Main position	Quantity	% Market Cap.
13/05/22	Cynthia Lucchese	Tender	Director	116,679	0.3453%
13/05/22	Dana Mead	Tender	Director	91,709	0.2714%
13/05/22	Patrick A. Broderick	Tender	General Counsel	92,105	0.2726%

Intersect ENT, Inc. Stock

Stocks

XENT

US46071F1030

Medical Equipment, Supplies & Distribution

Latest news : Intersect ENT, Inc.

Analysts' recommendations: Intersect ENT, Inc.

Press Releases: Intersect ENT, Inc.

News in other languages: Intersect ENT, Inc.

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERSECT ENT, INC.	-.--%	+1.51%	-	-	955M
ABBOTT LABORATORIES	+0.22%	+5.62%	-28.32%	-9.88%	167B
MEDTRONIC PLC	+0.93%	+7.16%	-4.38%	-2.40%	107B
CENCORA, INC.	+1.99%	+7.60%	+0.65%	+59.53%	59.24B
HOYA CORPORATION	-6.77%	-7.86%	+44.51%	+46.55%	52.99B
BECTON, DICKINSON AND COMPANY	+0.49%	+3.28%	-9.63%	-39.16%	43.07B
MEDLINE INC.	+0.61%	+9.05%	-	-	36.37B
DEXCOM, INC.	+1.64%	+9.24%	-11.30%	-41.94%	28.39B
WEST PHARMACEUTICAL SERVICES, INC.	-0.44%	-0.81%	+60.77%	-4.18%	25.16B
TERUMO CORPORATION	-2.04%	+1.90%	-7.08%	+5.37%	21.17B
Average	-0.34%	+4.89%	+5.65%	+1.74%	60.07B
Weighted average by Cap.	-0.13%	+5.25%	-4.28%	+2.41%